GBA-associated Parkinson’s disease in Hungary: clinical features and genetic insights

• Published in: Neurological sciences 2024-06, Vol.45 (6), p.2671-2679
• Main Authors: Szlepák, Tamás, Kossev, Annabel P., Csabán, Dóra, Illés, Anett, Udvari, Szabolcs, Balicza, Péter, Borsos, Beáta, Takáts, Annamária, Klivényi, Péter, Molnár, Mária J.
• Format: Article
• Language: English
• Subjects: Apolipoprotein E; Dementia disorders; Enzymatic activity; Genes; Genetic diversity; Genetic screening; Genotypes; Glucosylceramidase; Health risk assessment; Lewy bodies; Medicine; Medicine & Public Health; Movement disorders; Neurodegenerative diseases; Neurology; Neuroradiology; Neurosurgery; Original Article; Parkinson's disease; Psychiatry; Risk factors
• ISSN: 1590-1874; 1590-3478
• DOI: 10.1007/s10072-023-07213-w

Introduction Parkinson’s disease (PD) has a complex genetic background involving both rare and common genetic variants. Although a small percentage of cases show a clear Mendelian inheritance pattern, it is much more relevant to identify patients who present with a complex genetic profile of risk variants with different severity. The ß-glucocerebrosidase coding gene ( GBA1 ) is recognized as the most frequent genetic risk factor for PD and Lewy body dementia, irrespective of reduction of the enzyme activity due to genetic variants. Methods In a selected cohort of 190 Hungarian patients with clinical signs of PD and suspected genetic risk, we performed the genetic testing of the GBA1 gene. As other genetic hits can modify clinical features, we also screened for additional rare variants in other neurodegenerative genes and assessed the APOE-ε genotype of the patients. Results In our cohort, we identified 29 GBA1 rare variant (RV) carriers. Out of the six different detected RVs, the highly debated E365K and T408M variants are composed of the majority of them (22 out of 32). Three patients carried two GBA1 variants, and an additional three patients carried rare variants in other neurodegenerative genes ( SMPD1 , SPG11 , and SNCA ). We did not observe differences in age at onset or other clinical features of the patients carrying two GBA1 variants or patients carrying heterozygous APOE-ε4 allele. Conclusion We need further studies to better understand the drivers of clinical differences in these patients, as this could have important therapeutic implications.